• ABOUT
  • STRATEGIES
    • LIFE SCIENCES
    • CREDIT OPPORTUNITIES
  • TEAM
  • INVESTMENTS
  • CONTACT
  • INVESTOR LOGIN
    • PERCEPTIVE LIFE SCIENCES FUND
    • PERCEPTIVE CREDIT OPPORTUNITIES FUND
    • PERCEPTIVE XONTOGENY VENTURE FUND

INVESTMENTS

OUR INVESTMENTS

Perceptive invests in the technologies, leaders, and advancements that our team identifies as transformative within their fields. Our investment strategies are built upon extensive fundamental analysis and decades of experience investing in small to large-capitalization healthcare companies. Using data-driven scientific evaluations, we approach every step of development for new therapeutics, devices, or diagnostics with conviction.

  • PRIVATE EQUITY
    INVESTMENTS
  • PRIVATE EQUITY
    AQUIRED/IPO’D
  • PRIVATE CREDIT
    INVESTMENTS
  • PRIVATE CREDIT
    EXITS

BLACK DIAMOND THERAPEUTICS

Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations. The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies. Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.
blackdiamondtherapeutics.com.

BRIDGE BIO

We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases. Finding the right starting points to target diseases at their source.

Using a combination of a systematic assessment of the genetic disease landscape and informed diligence on the latest research, we find indications with clear mechanisms of pathogenesis that are ripe for translation into disease-modifying drugs.

bridgebio.com.

CENSA

Censa is developing therapies for orphan metabolic diseases with earlier stage programs targeting central nervous system diseases.
censapharma.com.

CRINETICS PHARMACEUTICALS

Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. A team of scientists with a proven track record of endocrine drug discovery and development founded the company to create important new therapeutic options for endocrinologists and their patients.
crinetics.com.

ESTABLISHMENT LABS

Establishment Labs is a women’s health company that manufactures and markets the Motiva line of breast implants.
establishmentlabs.com.

IDEAYA BIOSCIENCES

IDEAYA is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment.  Founded in 2015, the Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by three Members of the National Academy of Sciences.
ideayabio.com

KODIAK SCIENCES

Kodiak is a high-science retinal medicines development company. We are aspiring to build a dominant global retina franchise. We are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. Our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. In our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments.
kodiak.com

LANDOS BIOPHARMA

Landos’ unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases. Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.
landosbiopharma.com

MEIRAGTX

MeiraGTx develops innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. We are pioneering the use of gene therapy to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). MeiraGTx is developing novel gene regulation platforms that promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
meiragtx.com.

MOTUS

Motus GI is a medical device company focused on improving the patient experience and medical outcomes of colonoscopy procedures
motusgi.com.

OUTSET MEDICAL

Outset Medical is focused on reimagining the experience of dialysis care for patients with kidney disease by providing them greater flexibility, independence, and control with the potential to dramatically lower cost for providers and the healthcare system.
outsetmedical.com.

QSPEX

QSpex is transforming the vision industry by combining best-in-class lens technology with an unprecedented level of service. Transforming the optical industry by offering premium prescription eyewear, fulfilled SAME-DAY, through a personalized delivery and dispensing process. Our high-speed, proprietary Rapid Lens Technology™ eliminates the pitfalls of traditional lens manufacturing. Using QSpex’s groundbreaking Touchless Transfer™ lens system, Rapid Lens Technology™ provides premium prescription eyewear through unique, covalently bonded treatments.
qspex.com.

RENOVIA

Renovia was formed to better diagnose, treat, and potentially improve the lives of millions of women through a platform of innovative sensor technologies combined with a digital health platform. This allows precise, cost-effective visualization and treatment of weakened pelvic floor muscles in real time, while collecting actionable compliance and progress data on women’s pelvic health. Restoring pelvic health by strengthening pelvic floor muscles through clinically benefiting solutions is paramount to treating the underlying causes of Pelvic Floor Disorders.
renoviainc.com.

SOLID BIOSCIENCES

A private company focused on acquiring and developing disease modifying therapies for Duchenne Muscular Dystrophy through rigorous scientific analysis, efficient capital management and global collaborations.
solidbio.com.

TIVORSAN

Tivorsan Pharmaceuticals is a protein therapeutics company pioneering a unique approach to treat serious neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
tivorsan.com.

VAPOTHERM

Vapotherm is dedicated to the development, manufacture and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery cost and improve quality of life for patients. Vapotherm High Flow Therapy provides support for patients in respiratory distress and has been used in over half a million patients.
vtherm.com.

VENSUN PHARMACEUTICALS

Vensun Pharmaceuticals is an emerging generic pharmaceutical company developing a portfolio of difficult to access or hard to formulate generic prescription products.
vensunrx.com.

VERRICA PHARMACEUTICALS

Verrica Pharmaceuticals is a clinical-stage pharmaceutical company developing proprietary topical therapies for the treatment of skin diseases such as Verruca vulgaris (common warts and plantar warts) and Molluscum contagiosum. Current treatments for these and similar conditions have only limited efficacy, are painful or require daily compliance for an extended treatment period to see results.
verricapharmaceuticals.com

VITRUVIAS

Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.
vitruvias.com.

VYOME

Vyome Biosciences is an innovation driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development.
vyome.in.

XONTOGENY

Xontogeny (zon-TOJ-uh-nee) is a biotech aggregator with a differentiated business model to support the accelerated development of life science technologies in the pursuit of helping patients with serious diseases. Specifically, we partner with entrepreneurs, providing the leadership and operating experience needed to increase the probability of success with early drug and technology development.
xontogeny.com.

ZENEFITS

Zenefits is a cloud based healthcare insurance broker focused on gaining market share by providing small businesses with HR software for free.
zenefits.com.

ACERTA PHARMA

Acerta Pharma BV is a Biotech company that combines two technology platforms in drug discovery and development: the Covalent Technology Platform and the Multiparametric Phosphoflow Cytometry Platform. These platforms ensure rapid identification and optimization of high-quality drug candidates and enable administering the right drug to the right patient at the right dose.
acerta-pharma.com

BELLICUM

Bellicum’s CID Technology Enhances Potential of Cellular Immunotherapy Cell signaling switches enable control over immune activity. Bellicum’s unique technology, designed to give physicians control over cells and immune activity inside the body, aims to make cell therapies safer and more effective.
bellicum.com

BLUEPRINT MEDICINES

Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
blueprintmedicines.com

CORBUS PHARMACEUTICALS

A clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening (“orphan”) inflammatory-fibrotic diseases with clear unmet needs.
corbuspharma.com

DOVA

Dova is a clinical-stage pharmaceutical company developing treatments for patients suffering from orphan diseases.
dovapharmaceuticals.com

GENSIGHT

GenSight is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
gensight-biologics.com

GLOBAL BLOOD THERAPEUTICS (GBT)

Global Blood Therapeutics (GBT) is a clinical stage biopharmaceutical company developing novel small molecule therapeutics to treat grievous, non-malignant blood-based conditions for which there are currently only limited therapy.
globalbloodtx.com

INVITAE

A genetic information company making genetic testing more affordable and accessible than ever before by lowering the barriers to genetic results for clinicians and patients.
invitae.com

KADMON

Kadmon is a biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Founded in 2009, Kadmon has pioneered a new approach to the traditional biotechnology model by building, from inception, a vertically integrated company comprising innovative drug discovery platforms, a deep clinical pipeline and a commercial operation with specialty pharmaceutical products.
kadmon.com

MYOKARDIA

MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
myokardia.com

ONCOBIOLOGICS

Oncobiologics is a complex biosimilar company focused on developing technically challenging biosimilars in a cost effective way. The first wave of Phase 3 ready products include ONS-3010 (Humira® Biosimilar) and ONS-1045 (Avastin® Biosimilar).
oncobiologics.com

OTONOMY

Otonomy’s mission is to develop and commercialize novel and best-in-class therapeutics to address unmet medical needs in the emerging otology market, which overcome many of the limitations of delivering drugs to the middle and inner ear.
otonomy.com

TRUE NORTH THERAPEUTICS

True North is guided by the needs of patients as we discover life-changing medicines for rare diseases. We combine scientific and clinical expertise in diseases of the Complement system so that we can rapidly develop new drugs for rare diseases with few, if any, treatment options. Our R&D is focused on finding novel drugs for rare diseases in which complement is a key driver of pathogenesis. We concentrate on therapies that can intervene upstream in the Complement system, selectively targeting the pathway underlying the disease.
truenorthrx.com

VBI VACCINES

A biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. The vaccine platform allows for the design of vaccines that closely mimic the target virus. VBI has also completed proof of concept thermostability studies on a number of vaccine and biologic.
vbivaccines.com.

VERSARTIS

A biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders utilizing the novel half-life extension technology, XTEN, in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD).
versartis.com

ZYMEWORKS

Zymeworks is committed to the development of best in class antibody and protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.
zymeworks.com

ZYNERBA PHARMACEUTICALS

Zynerba Pharmaceuticals is dedicated to the development of next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery for patients with significant medical need. Their mission is to improve the lives of patients battling severe health conditions including peripheral neuropathic pain, fibromyalgia, chronic cancer pain, refractory epilepsy and osteoarthritis through synthetic cannabinoid therapeutics formulated for transdermal delivery.
zynerba.com

ACCUVEIN

AccuVein is a global leader in medical imaging solutions. Vein illumination with our breakthrough device, allows health care professionals to see a map of peripheral veins on the skin’s surface with the goal of improving venipuncture, the most commonly performed invasive medical procedure, and other vascular access procedures.
accuvein.com

AEGEA MEDICAL

AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-based procedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare.
aegeamedical.com

ALLIQUA BIOMEDICAL

Alliqua Biomedical is a leading provider of advanced wound care solutions. The company is building a portfolio through targeted acquisitions and through licensing and distribution agreements with their strategic partner Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation.
alliqua.com

CAREDX

CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.
caredx.com

COUNSYL

We believe in the power of technology to make people healthier. Using just a small amount of saliva or blood, we can give you access to the information stored in your DNA and, most importantly, help you understand what it means. We’re working to make DNA screening just as simple, and just as common, as going to the doctor for a physical. By keeping costs low and providing results in straightforward, easy-to-understand language we’re putting potentially life-changing information within everyone’s reach.
counsyl.com

EIDOS THERAPEUTICS

Eidos Therapeutics is a clinical biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. Eidos seeks to treat this well-defined family of diseases at their collective source by stabilizing TTR.
eidostx.com

KADMON

Kadmon is a biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Founded in 2009, Kadmon has pioneered a new approach to the traditional biotechnology model by building, from inception, a vertically integrated company comprising innovative drug discovery platforms, a deep clinical pipeline and a commercial operation with specialty pharmaceutical products.
kadmon.com

MOLECULAR TEMPLATES

Molecular Templates is focused on the discovery, development and commercialization of next generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancer. ETBs platform represents a new class of targeted biologic therapy with unique biological properties.
mtem.com

AQUESTIVE

Aquestive is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films.
aquestive.com

PARTNER THERAPEUTICS

PTx has acquired the global rights to develop, manufacture, and commercialize Leukine from Sanofi. Leukine is a multi-lineage immune-stimulant that has been demonstrated to promote growth and activation of monocytes, macrophages, neutrophils and dendritic cells. It is the only FDA-approved recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF). Leukine is currently being tested in over 100 clinical studies to assess its ability to increase the efficacy of immuno-oncology therapies, improve the treatment of pulmonary and neurological disorders, and improve the treatment of infections. PTx is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer.
partnertx.com

PROCEPT BIOROBOTICS

PROCEPT BioRobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on benign prostatic hyperplasia (BPH), PROCEPT has developed Aquablation® therapy, a novel and disruptive treatment for enlarged prostate. The company’s first product, the AquaBeam® System, is the world’s first surgical robot providing autonomous tissue removal for the safe and effective treatment of BPH, independent of prostate anatomy or surgeon experience.
procept-biorobotics.com

SINGULEX

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Sgx Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The Sgx Clarity system and Sgx Clarity assay received CE mark in 2017 and are commercially available in Europe; additional assays to detect and rule out infectious and inflammatory diseases are in development. Singulex is also developing a point-of-care platform and exploring applications beyond the clinical setting.
singulex.com

SONENDO

With breakthrough Multisonic Ultracleaning™ technology, Sonendo® is elevating the level of clean throughout endodontics and dentistry. By introducing broad spectrum acoustic technology and reducing doctors’ reliance on standard instrumentation, Sonendo is saving teeth, transforming dentistry and changing patients’ lives.
sonendo.com

AFFIMED

A clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. The company engineers and develops next-generation bispecific antibodies that bind with high specificity and affinity to certain cancer cells and direct the most potent cells of the human immune defense arsenal, to attack and kill cancer cells.
affimed.com.

RETROPHIN

A biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options.
retrophin.com.

VITALCONNECT

Headquartered in the heart of Silicon Valley, California, VitalConnect was founded in 2011 with a vision of changing the paradigm of healthcare as we know it by creating a new world of information with predictive data analytics at everyone’s fingertips.
vitalconnect.com.

STOKE THERAPEUTICS

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
stoketherapeutics.com.

MEDICREA

At Medicrea, creativity is our highest priority, because we believe in the inventive power of our engineers and surgeon partners working together. (IM)PROVE. It extends from designing and manufacturing next-generation spinal implants, with enhanced functionalities and quality testing, to providing more effective and less invasive treatments for all spinal pathologies. Our aim is to restore the long-term quality of life for patients. Our extensive range of spinal implants addresses spinal pathologies at all levels, from cervical to lumbar and sacrum. Our implants are designed to treat scoliosis, degenerative deformation, trauma and tumors, regardless of severity, and can be used in all traditional and advanced surgical techniques, such as minimally-invasive surgery. We benefit from the support of renowned surgeons who are also closely involved in designing our prostheses as well as the support of healthcare agencies.
medicrea.com.

RELAY THERAPEUTICS

This leap forward in drug discovery allows Relay Therapeutics to leverage the relationship between protein motion and function, creating opportunities to develop more effective therapies for multiple diseases. Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
relaytx.com.

RAIN THERAPEUTICS

Rain Therapeutics aim to identify cancers with a single, and clear, oncogenic driver and evaluate sub-populations of cancer populations with an unmet need, where standards of care are ineffective.
rainthera.com.

4D MOLECULAR TEMPLATES

At 4DMT we are creating and developing optimized “biopharmaceutical grade” AAV vectors that will allow us uniquely to unlock the full potential of gene therapy. Our customized and proprietary AAV vectors are each designed, according to a 4DMT Target Vector Profile, to deliver genes to specific cells and tissues in the body to eradicate both rare and large market diseases.
4dmoleculartherapeutics.com.

LYRA THERAPEUTICS

Lyra Therapeutics is a clinical-stage company developing medicines precisely designed to target ear, nose and throat (ENT) diseases. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients.
lyratherapeutics.com.

ORCHESTRA BIOMED

Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, affect large patient populations and drive a significant portion of healthcare costs. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide
.
orchestrabiomed.com.

REVIRAL

The ReViral team has an extensive track record in the discovery and development of antiviral therapies. We work closely with key collaborators and consultants to transform the lives of patients and families affected by life-threatening viral infections.
reviral.co.uk.

PHOSPHORUS

Building a network of human genomes to bridge the gap between our DNA and our health.
phosphorus.com.

ATHENEX

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, that can have a life-changing impact on cancer patients.
athenex.com.

ALLOGENE

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
allogene.com.

ORCHARD THERAPEUTICS

Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
orchard-tx.com.

Information listed is as of January 1, 2018. The portfolio companies shown represent a portion of private equity investments made in the Perceptive Advisors’ Life Sciences strategy and/or the Perceptive Advisors’ Credit Opportunities strategy. Companies are included for purpose of illustration and do not represent a full list of private investments made in the strategy.
We apply a disciplined, long-term focus
while remaining on the front line of
emerging biotech breakthroughs.
We apply a disciplined, long-term focus while remaining on the front line of emerging biotech breakthroughs.
  • Perceptive Advisors
  • 51 Astor Place, 10th floor
    New York, NY 10003
    Phone: (646) 205-5300
  • DISCLAIMER
  • ONLINE PRIVACY POLICY
  • TERMS AND CONDITIONS

Site designed by Case Study Brands